PE20070603A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA) - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)

Info

Publication number
PE20070603A1
PE20070603A1 PE2006000566A PE2006000566A PE20070603A1 PE 20070603 A1 PE20070603 A1 PE 20070603A1 PE 2006000566 A PE2006000566 A PE 2006000566A PE 2006000566 A PE2006000566 A PE 2006000566A PE 20070603 A1 PE20070603 A1 PE 20070603A1
Authority
PE
Peru
Prior art keywords
inhibitor
coa
hmg
reductase
hydroxy
Prior art date
Application number
PE2006000566A
Other languages
English (en)
Inventor
Tomoyuki Nishimoto
Ryuichi Tozawa
Eiichiro Ishikawa
Hiroko Iino
Takeo Wada
Toshiya Nishi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20070603A1 publication Critical patent/PE20070603A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE ESCUALENO SINTASA DE FORMULA (I) DONDE R1 ES H O UN GRUPO HIDROCARBURO; R2 Y R3 SON CADA UNO H, HETEROCICLICO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; X' ES CARBOXILO, CARBAMOILO, OH, NH, ENTRE OTROS; A ES BENCENO O HETEROCICLICO OPCIONALMENTE SUSTITUIDO; J' ES UN ANILLO HETEROCICLICO DE 7 O 8 MIEMBROS; SIENDO UN COMPUESTO PREFERIDO EL ACIDO N-[[(3R,5S)-1-(3-ACETOXI-2,2-DIMETILPROPIL)-7-CLORO-5-(2,3-DIMETOXIFENIL)-2-OXO-1,2,3,5-TETRAHIDRO-4,1-BENZOXAZEPIN-3-IL]ACETIL]PIPERIDIN-4-ACETICO; Y B) UN INHIBIDOR DE LA ENZIMA 3-HIDROXI-3-METILGLUTARIL COENZIMA A (HMG-CoA) REDUCTASA TAL COMO ATORVASTATINA, LOVASTATINA, SIMVASTATINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERLIPIDEMIA
PE2006000566A 2005-06-01 2006-05-31 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA) PE20070603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68587105P 2005-06-01 2005-06-01
US72832905P 2005-10-20 2005-10-20

Publications (1)

Publication Number Publication Date
PE20070603A1 true PE20070603A1 (es) 2007-06-22

Family

ID=36699172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000566A PE20070603A1 (es) 2005-06-01 2006-05-31 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)

Country Status (17)

Country Link
US (1) US20090209510A1 (es)
EP (1) EP1962832A2 (es)
JP (1) JP2008542191A (es)
KR (1) KR20080012916A (es)
AR (1) AR054368A1 (es)
AU (1) AU2006253255A1 (es)
BR (1) BRPI0610484A2 (es)
CA (1) CA2609784A1 (es)
CR (1) CR9521A (es)
IL (1) IL187207A0 (es)
MA (1) MA29531B1 (es)
MX (1) MX2007014730A (es)
NO (1) NO20076566L (es)
PE (1) PE20070603A1 (es)
RU (1) RU2007149337A (es)
TW (1) TW200714280A (es)
WO (1) WO2006129859A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
NZ587019A (en) * 2008-01-10 2012-07-27 Takeda Pharmaceutical Capsule formulation
CA2868372A1 (en) 2011-04-08 2012-10-11 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
US11833133B2 (en) 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
WO1994007485A1 (en) * 1992-10-06 1994-04-14 Merck & Co., Inc. Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
RU2040932C1 (ru) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
EP0862562B1 (en) * 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US20030078251A1 (en) * 2000-06-23 2003-04-24 Masakuni Kori Benzoxazepinones and their use as squalene synthase inhibitors
CA2428669A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
EP1249230B1 (de) * 2001-04-12 2003-11-05 Vesifact Ag Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
WO2004064865A1 (ja) * 2003-01-17 2004-08-05 Takeda Pharmaceutical Company Limited 骨格筋保護剤

Also Published As

Publication number Publication date
WO2006129859A3 (en) 2007-04-19
US20090209510A1 (en) 2009-08-20
WO2006129859A2 (en) 2006-12-07
TW200714280A (en) 2007-04-16
EP1962832A2 (en) 2008-09-03
JP2008542191A (ja) 2008-11-27
IL187207A0 (en) 2008-06-05
NO20076566L (no) 2008-02-22
CA2609784A1 (en) 2006-12-07
AR054368A1 (es) 2007-06-20
KR20080012916A (ko) 2008-02-12
MA29531B1 (fr) 2008-06-02
CR9521A (es) 2008-02-22
MX2007014730A (es) 2008-02-15
RU2007149337A (ru) 2009-07-10
AU2006253255A1 (en) 2006-12-07
BRPI0610484A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
PE20070603A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
EA201000958A1 (ru) Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i
PE20011294A1 (es) Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
UA98966C2 (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
RS53523B1 (en) ANILINE-PYRIMIDINE DERIVATIVES WITH SUBSTITUTED SULFOXIMIN AS CDK INHIBITORS, THEIR PRODUCTION AND USE AS MEDICINES
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
WO2012002741A3 (en) Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
PE20060184A1 (es) Derivados de imidazoles como inhibidores de la sintesis del colesterol
PE20061121A1 (es) Compuestos derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamidas
PE20061057A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE HMG CoA REDUCTASA
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.
DK1478650T3 (da) Nye boronatestere
EA200501881A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ HMG-CoA
WO2008010087A3 (en) Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
BRPI0411293A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto

Legal Events

Date Code Title Description
FC Refusal